24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Women May Be More Willing Than Men to Donate OrgansDNA Sensor Can Spot When COVID Is ContagiousTrials Show COVID Vaccines Well Worth It for Cancer PatientsCDC Endorses Booster Shots for Millions of AmericansChildhood Trauma Linked With Higher Odds for Adult Neurological IllsStudy Probes Relationship Between Migraines and SleepCancer in Hispanics: Good News and BadFDA Approves Pfizer Booster Shots for Seniors, High-Risk AmericansU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationAntibodies to Early Strains of COVID May Not Fight New Variants: StudyPregnant Women Who Get COVID Vaccine Pass Antibodies to NewbornsCDC Expert Panel to Weigh In on Vaccine BoostersWhich Kids Are at Highest Risk From COVID?4 Out of 10 Adults With No Known Heart Disease Have Fatty Hearts: StudyBooster Dose of J&J COVID Vaccine Increases ImmunityPost-Stroke Rehab: There's a Sweet Spot in the TimingCommon Form of Liver Cancer on the Rise in Rural AmericaCOVID Has Killed More Americans Than the Spanish Flu Did in 1918Telemedicine Gets High Marks for Follow-Ups After SurgeryPandemic Tied to Declining Birth Rates for U.S., Much of EuropeStudy Spots People at High Risk of Severe Breakthrough COVIDReview of Booster Shots for Moderna, J&J Vaccines Just Weeks Away: FauciDelta Variant Now Fueling 99% of U.S. COVID CasesLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysFDA Panel OKs Pfizer Booster Shot forĀ  People 65 or Older, But Not YoungerLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyPfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: StudyTrial Into Antioxidant for Parkinson's Disease Yields Disappointing ResultsIs Flu Ready for a Comeback? Get Your ShotCommon Eye Conditions Tied to Higher Risk for DementiaDrug Might Stop Heart Trouble Linked to Sickle Cell AnemiaChild Obesity Rose Sharply During PandemicFDA Advisory Panel to Meet on COVID Booster ShotsStatin Cholesterol Drugs May Help Fight Ulcerative ColitisAHA News: Physical Activity Is Helpful After a Stroke, But How Much Is Healthy?Special 'Strategies' Can Help People With Parkinson's Walk, But Many Patients UnawareEven When Undergoing Treatment, People With MS Gain From COVID VaccinesNIH Spending Nearly $470 Million on Long-Haul COVID StudyHospitalizing the Unvaccinated Has Cost U.S. Nearly $6 BillionIn 16 States, 35% or More Residents Now Obese: CDCPet Store Puppies Passing Drug-Resistant Bacteria to PeopleIs a Combo COVID/Flu Shot on the Way?1 in 500 Americans Has Died From COVID-19Having Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyWHO Says Africa Will Get 30% of COVID Vaccines It Needs by FebruaryCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciEbola Vaccine Effective in African Clinical TrialBritain OK's COVID Vaccine for Kids 12 and Older; Hopes to Avoid LockdownsIsraeli Data on COVID Boosters to Be Published This Week in Major Journal
Questions and AnswersLinks
Related Topics

Diabetes

Any COVID Infection Leaves Strong Antibody Levels in Kids

HealthDay News
by Robert Preidt
Updated: Jul 19th 2021

new article illustration

MONDAY, July 19, 2021 (HealthDay News) -- Even a mild or asymptomatic case of COVID-19 triggers a strong antibody response in children and teens, new research shows.

"These findings are encouraging, especially because we cannot yet vaccinate children under the age of 12 against the virus," said study co-lead author Jillian Hurst, an assistant professor in the Department of Pediatrics at Duke University School of Medicine in Durham, N.C.

"The study shows that children who've had mild infections or even those who did not have any symptoms, develop an immune response that will likely provide some protection against future infections," Hurst said in a university news release.

She and her colleagues measured antibody response in 69 young patients, aged 2 months to 21 years, with asymptomatic and mild symptomatic SARS-CoV-2 infection. The median age was 11.5 years, and 51% were female.

Antibody response in the children did not differ based on the presence of symptoms, and antibodies against the coronavirus were still present in most of participants up to four months after infection.

The researchers also found that regardless of age, the children's antibody levels were the same or slightly higher than adults at two and four months after infection, according to the study published recently in the journal JCI Insight.

The findings suggest that giving COVID-19 vaccines to young children could lead to a level of antibody protection that's similar to or greater than that of adults, the researchers noted.

"Most studies of the immune responses of children to SARS-CoV-2 have focused on patients hospitalized for severe COVID-19 or multi-system inflammatory syndrome in children [MIS-C], or have assessed immunity only during acute infection," said study senior author Dr. Genevieve Fouda, an associate professor in the Departments of Pediatrics and Molecular Genetics and Microbiology at Duke.

"Our study provides important information that SARS-CoV-2-specific immune responses, regardless of disease severity, may decline over time more slowly in children and adolescents," Fouda said in the release.

More information

The American Academy of Pediatrics has more on COVID-19.

SOURCE: Duke University, news release, July 16, 2021